Abstract
Abstract Background Magnetic sphincter augmentation (MSA) has been proven a safe and efficient alternative to laparoscopic Nissen fundoplication (LNF) in patients with gastro-intestinal reflux disease (GERD). Aim of this study was to compare the matched outcome of patients with GERD following MSA and LNF, respectivelyMagnetic sphincter augmentation (MSA) has been proven a safe and efficient alternative to laparoscopic Nissen fundoplication (LNF) in patients with gastro-intestinal reflux disease (GERD). Aim of this study was to compare the matched outcome of patients with GERD following MSA and LNF, respectively Methods Out of a prospective database, an analysis was conducted including patients that underwent MSA and LNF, respectively, between 2012 and 2017 at our institution. Patients were matched using propensity scores including selected criteria. Postoperative outcomes were assessed through reflux-symptoms, proton pump inhibitor (PPI) intake, GERD-Health-related-Quality-of-Life (GERD-HRQL) and Alimentary Satisfaction (AS). Results From a total of 323 patients, 186 patients that met our inclusion criteria were matched. At a median follow-up of 1.5 years there was no difference in the GERD-HRQL (2.5 MSA vs. 1 LNF, P = 0.341), AS (8/10 MSA vs 9/10 LNF, P = 0.175), regular PPI-intake (15% MSA vs. 6% LNF, P = 0.058) or heartburn elimination (73% MSA and LNF) between the two groups. We observed similar side-effect rates concerning persistent dysphagia (1% MSA and LNF) and gas-bloating (17% MSA vs. 15% LNF, P = 0.690). However, in patients after MSA the ability to belch and/or vomit was higher (87% MSA vs. 70% LNF, P = 0.05). Conclusion Mid-term outcome of patients after MSA for the treatment of GERD is comparable to patients treated with LNF. Patients after MSA showed a higher ability to belch and/or vomit when compared to patients after LNF. This study encourages MSA as alternative first-line treatment in patients with non-severe GERD Disclosure All authors have declared no conflicts of interest.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
